October 9, 2020

GLOBSEC conference backed with MultiplexDX COVID-19 tests

Globsec tested hundreds of people with partners in one day. The organizers and staff of the conference are about seven hundred people. A maximum of 250 guests were expected to be among the conference participants. Conference guests were also offered pre-departure testing to make sure they are returning home healthy.

The organizers consulted the preparation of the conference with the Public Health Office and the Council of Epidemiologists and decided to test everyone with the help partners. Globsec organizers decided to use mix of rapid antigen tests and PCR testing.

PCR tests developed in Slovakia were sponsored by MultiplexDX, led by the well-known Slovak scientist Pavol Čekan and physically performed by the Virological Institute of the BMC of the Slovak Academy of Sciences

About MultiplexDX

MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).

MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.

Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter

Other latest

MultiplexDX News